B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S

B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S

Summary: The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, even...

Full description

Bibliographic Details
Main Authors: Catherine Jacob-Dolan, Michelle Lifton, Olivia C. Powers, Jessica Miller, Nicole P. Hachmann, Mya Vu, Nehalee Surve, Camille R. Mazurek, Jana L. Fisher, Stefanie Rodrigues, Robert C. Patio, Trisha Anand, Mathieu Le Gars, Jerald Sadoff, Aaron G. Schmidt, Dan H. Barouch
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:iScience
Subjects:
Health sciences
Immunity
Immune response
Virology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004224009386

Internet

http://www.sciencedirect.com/science/article/pii/S2589004224009386

Similar Items